GREATER DEPRESSIVE SYMPTOMS PREDICT ADHERENCE TO AROMATASE INHIBITOR THERAPY IN POST-MENOPAUSAL WOMEN WITH BREAST CANCER

Authors: Michelle Sech, BSN Candidate, Amanda Gentry, MPH, Maura Mccall, RN, MSN, Susan Sereika, PhD, Yehui Zhu, MSN, Catherine Bender, PhD, RN, FAAN Mentor: Catherine Bender, PhD, RN, FAAN Professor, Nursing and Clinical and Translational Science Institute Nancy Glunt Hoffman Endowed Chair in Oncology Nursing University of Pittsburgh School of Nursing 3500 Victoria Street Pittsburgh, PA 15261

Background: Depressive symptoms are commonly reported in women breast cancer and may affect their ability to adhere to endocrine (aromatase inhibitor; AI) therapy. Few studies have examined the correlation between depressive symptoms and AI therapy adherence in women with breast cancer. The purpose of this secondary analysis is to examine the relationship between depressive symptoms and subsequent adherence to AI therapy. Methods: Depressive symptoms were assessed in post-menopausal women with early stage breast cancer before beginning and 6 months post-initiation of AI therapy using the total score from The Beck Depression Inventory (BDI-II), a 21 item self-report measure of symptoms characteristic of depression; higher scores are indicative of more severe depressive symptoms. Adherence to AI therapy was measured over the first 12 months of treatment via a Medication Event Monitoring System (MEMS cap), which collected continuous data about event openings. Data were summarized into the percent of days women were adherent over the first and second 6 months of therapy. Spearman’s rank-order correlation was employed to examine the relationship between depressive symptoms and adherence to AI therapy over the following 6 months, with the level of statistical significance set at .05. Results: Participants (N=283) were 61 years of age on average with 15 years of education, married (71%), mostly white (97%), and diagnosed with stage I breast cancer (67%). A small but significant correlation was detected between pre-AI depressive symptoms and adherence over the first 6 months (r= -.119; p=.049) and between depressive symptoms 6 months post-initiation of therapy and adherence over the following 6 months (r= -.207; p=.002) where greater depressive symptoms were related to poorer adherence. Conclusion: Our results suggest that women with greater severity of depressive symptoms are at a higher risk for non-adherence to therapy. Findings may help clinicians identify patients at risk for non-adherence.


Additional Abstract Information

Presenter: Michelle Sech

Institution: University of Pittsburgh School of Nursing

Type: Oral

Subject: Nursing

Status: Approved


Time and Location

Session: Oral 6
Date/Time: Fri 10:25am-10:45am
Location: Old North 211
List other presenters in this same room and session